Company overview
ERS Genomics licenses foundational CRISPR/Cas9 intellectual property from Nobel Laureates Emmanuelle Charpentier and Jennifer Doudna, covering over 85 patents worldwide. The company provides non-exclusive licenses for research and commercial applications outside direct human gene and cell therapy, supporting biotech, pharma, agriculture, and synthetic biology. It offers an Express License platform for fast, affordable access tailored to startups and small research enterprises.
ERS Genomics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include crispr licensing, cas9 patents, gene editing ip, ers genomics, crispr/cas9 technology.
Structured facts
- Website
- https://www.ersgenomics.com
- Markets served
- United States & Americas
- Keywords
- crispr licensing, cas9 patents, gene editing ip, ers genomics, crispr/cas9 technology
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What CRISPR/Cas9 licensing options does ERS Genomics provide?
- ERS Genomics offers non-exclusive licenses for internal research and commercial uses outside direct human therapeutics, including an Express License platform for quick access via online application for eligible startups and small enterprises.
- Which industries and applications are covered by ERS Genomics licenses?
- Licenses support biotech, pharma, agriculture, synthetic biology, preclinical model development, base editing, prime editing, and CRISPR-based gene regulation for freedom-to-operate under foundational patents.
- How can companies obtain a CRISPR/Cas9 license from ERS Genomics?
- Companies negotiate licenses for research and commercial use or apply for Express Licenses online by demonstrating eligibility through publications, collaborations, or patents; ERS focuses solely on IP licensing, not technology provision.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
